CLDX (Celldex Therapeutics) Construction In Progress: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLDX Celldex Therapeutics Inc CLDX
45 GF Score
Price $44.53
GF Value $0.59
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Celldex Therapeutics Construction In Progress?

Celldex Therapeutics CLDX +0.43% 45 Construction In Progress is $0.00 Mil as of Jun. 2026. GuruFocus rates CLDX with a GF Score™ of 45/100 and a GF Value™ of $0.59 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Celldex Therapeutics's quarterly construction in progress declined from Dec. 2025 ($1.72 Mil) to Mar. 2026 ($0.00 Mil) but then stayed the same from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.00 Mil).

Celldex Therapeutics's annual construction in progress declined from Dec. 2023 ($0.79 Mil) to Dec. 2024 ($0.14 Mil) but then increased from Dec. 2024 ($0.14 Mil) to Dec. 2025 ($1.72 Mil).

Celldex Therapeutics Construction In Progress Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Construction In Progress Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.50 0.79 0.14 1.72

Celldex Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1.72 0.00 0.00
CLDX
45GF Score
Celldex Therapeutics Inc CLDX
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.00 Mil mean?
Celldex Therapeutics (CLDX) has a Construction In Progress of $0.00 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Celldex Therapeutics and its competitors.
Is Celldex Therapeutics' Construction In Progress too high?
Celldex Therapeutics' current Construction In Progress is $0.00 Mil. Overall, Celldex Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Celldex Therapeutics' Construction In Progress compare to IRON and QURE?
Celldex Therapeutics' Construction In Progress of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Celldex Therapeutics and its competitors. Celldex Therapeutics's current Construction In Progress is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celldex Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Celldex Therapeutics (CLDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.59, compared to a current price of $44.53 — trading 7447.5% above its estimated fair value. The current Construction In Progress is $0.00 Mil. Celldex Therapeutics' overall GF Score™ is 45/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Celldex Therapeutics (CLDX), the current Construction In Progress is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $44.53 is trading 7447.5% above its estimated GF Value™ of $0.59. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Construction In Progress: $0.00 Mil
  • GF Value™: $0.59 vs. price of $44.53 (7447.5% above fair value)
  • GF Score™: 45/100 with 9 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
45GF Score

Get the complete analysis for CLDX

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.53
Price
$0.59
GF Value